SCHEMBL4606033

SCHEMBL4606033

CCC(=O)Nc1ccc(Nc2ccccc2OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.47
IGF2BP2 Q9Y6M1 1/20 0.45
ALDH1A1 P00352 5/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
F2R P25116 1/20 0.43
KDM4E B2RXH2 6/20 0.43
HSD17B10 Q99714 2/20 0.43
TAS2R14 Q9NYV8 2/20 0.43
AURKA O14965 1/20 0.43
CTSV O60911 2/20 0.43
CTSL P07711 2/20 0.43
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
GAA P10253 2/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606034 0.83 IGF2BP2 (0.51) RORCIGF2BP2ALDH1A1SMN1; SMN2F2R
SCHEMBL5712901 0.83 AKR1C3 (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4604701 0.81 IGF2BP2 (0.48) IGF2BP2ALDH1A1KDM4EHSD17B10GAA
SCHEMBL4606525 0.81 CTSV (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL24939298 0.81 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2F2RKDM4EGAA
SCHEMBL4604536 0.80 RXRA (0.57) RORCIGF2BP2ALDH1A1F2RKDM4E
SCHEMBL4604961 0.80 ALDH1A1 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4604124 0.79 KCNK2 (0.42) RORCIGF2BP2ALDH1A1NPC1RAB9A
SCHEMBL4604597 0.78 FFAR1 (0.51) RORCIGF2BP2ALDH1A1SMN1; SMN2F2R
SCHEMBL4605958 0.78 KDM4E (0.42) RORCIGF2BP2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 RORC 56/4885IGF2BP2 3325/4885ALDH1A1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.